Phase III testing of Moderna's candidate SARS-CoV-2 vaccine has started today, NPR reports.
The trial will involve some 30,000 people, half of whom will receive two injections of the candidate vaccine, dubbed mRNA-1273, and half of whom will receive a saline placebo. Researchers will then monitor whether the vaccine can prevent those who receive it from becoming ill with COVID-19.